APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Recombinant Human Coagulation Factor IX

Compare research editions
View pricing & licenses

Selected research

Industry Research

Recombinant Human Coagulation Factor IX Industry Research Report 2026

Report ID 174031480523 December 2025134 pages

Choose your research edition.

Industry ResearchRecombinant Human Coagulation Factor IX Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Recombinant Human Coagulation Factor IX Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Recombinant Human Coagulation Factor IX Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Recombinant Human Coagulation Factor IX Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Recombinant Human Coagulation Factor IX Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Recombinant Human Coagulation Factor IX market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Recombinant Human Coagulation Factor IX is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Recombinant Human Coagulation Factor IX is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Recombinant Human Coagulation Factor IX is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Recombinant Human Coagulation Factor IX include Bio-Techne, Cayman, Cusabio, Grifols, IDELVION, NovoPro Bioscience, Octapharma, Sino Biological and Baxter, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Recombinant Human Coagulation Factor IX market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Recombinant Human Coagulation Factor IX Market by Company

Bio-Techne

Cayman

Cusabio

Grifols

IDELVION

NovoPro Bioscience

Octapharma

Sino Biological

Baxter

Biogen

Diagbio

Hualan Bio

Sanofi

ChinaBiologic

Shuyang

Recombinant Human Coagulation Factor IX Segment by Type

500 IU/Bottle

250 IU/Bottle

2000 IU/Bottle

1000 IU/Bottle

Recombinant Human Coagulation Factor IX Segment by Application

Adult Patients

Child Patients

Recombinant Human Coagulation Factor IX Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Recombinant Human Coagulation Factor IX market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Recombinant Human Coagulation Factor IX and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Recombinant Human Coagulation Factor IX.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Recombinant Human Coagulation Factor IX manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Recombinant Human Coagulation Factor IX by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Recombinant Human Coagulation Factor IX in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Recombinant Human Coagulation Factor IX Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Recombinant Human Coagulation Factor IX Sales (k units) of Manufacturers (2021-2026) Table 7. Global Recombinant Human Coagulation Factor IX Sales Market Share by Manufacturers (2021-2026) Table 8. Global Recombinant Human Coagulation Factor IX Revenue of Manufacturers (2021-2026) Table 9. Global Recombinant Human Coagulation Factor IX Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Recombinant Human Coagulation Factor IX Average Price (USD/unit) of Manufacturers (2021-2026) Table 11. Global Recombinant Human Coagulation Factor IX Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Recombinant Human Coagulation Factor IX, Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Recombinant Human Coagulation Factor IX, Product Type & Application Table 14. Global Recombinant Human Coagulation Factor IX Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Recombinant Human Coagulation Factor IX by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Bio-Techne Company Information Table 19. Bio-Techne Business Overview Table 20. Bio-Techne Recombinant Human Coagulation Factor IX Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 21. Bio-Techne Recombinant Human Coagulation Factor IX Product Portfolio Table 22. Bio-Techne Recent Developments Table 23. Cayman Company Information Table 24. Cayman Business Overview Table 25. Cayman Recombinant Human Coagulation Factor IX Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 26. Cayman Recombinant Human Coagulation Factor IX Product Portfolio Table 27. Cayman Recent Developments Table 28. Cusabio Company Information Table 29. Cusabio Business Overview Table 30. Cusabio Recombinant Human Coagulation Factor IX Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 31. Cusabio Recombinant Human Coagulation Factor IX Product Portfolio Table 32. Cusabio Recent Developments Table 33. Grifols Company Information Table 34. Grifols Business Overview Table 35. Grifols Recombinant Human Coagulation Factor IX Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 36. Grifols Recombinant Human Coagulation Factor IX Product Portfolio Table 37. Grifols Recent Developments Table 38. IDELVION Company Information Table 39. IDELVION Business Overview Table 40. IDELVION Recombinant Human Coagulation Factor IX Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 41. IDELVION Recombinant Human Coagulation Factor IX Product Portfolio Table 42. IDELVION Recent Developments Table 43. NovoPro Bioscience Company Information Table 44. NovoPro Bioscience Business Overview Table 45. NovoPro Bioscience Recombinant Human Coagulation Factor IX Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 46. NovoPro Bioscience Recombinant Human Coagulation Factor IX Product Portfolio Table 47. NovoPro Bioscience Recent Developments Table 48. Octapharma Company Information Table 49. Octapharma Business Overview Table 50. Octapharma Recombinant Human Coagulation Factor IX Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 51. Octapharma Recombinant Human Coagulation Factor IX Product Portfolio Table 52. Octapharma Recent Developments Table 53. Sino Biological Company Information Table 54. Sino Biological Business Overview Table 55. Sino Biological Recombinant Human Coagulation Factor IX Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 56. Sino Biological Recombinant Human Coagulation Factor IX Product Portfolio Table 57. Sino Biological Recent Developments Table 58. Baxter Company Information Table 59. Baxter Business Overview Table 60. Baxter Recombinant Human Coagulation Factor IX Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 61. Baxter Recombinant Human Coagulation Factor IX Product Portfolio Table 62. Baxter Recent Developments Table 63. Biogen Company Information Table 64. Biogen Business Overview Table 65. Biogen Recombinant Human Coagulation Factor IX Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 66. Biogen Recombinant Human Coagulation Factor IX Product Portfolio Table 67. Biogen Recent Developments Table 68. Diagbio Company Information Table 69. Diagbio Business Overview Table 70. Diagbio Recombinant Human Coagulation Factor IX Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 71. Diagbio Recombinant Human Coagulation Factor IX Product Portfolio Table 72. Diagbio Recent Developments Table 73. Hualan Bio Company Information Table 74. Hualan Bio Business Overview Table 75. Hualan Bio Recombinant Human Coagulation Factor IX Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 76. Hualan Bio Recombinant Human Coagulation Factor IX Product Portfolio Table 77. Hualan Bio Recent Developments Table 78. Sanofi Company Information Table 79. Sanofi Business Overview Table 80. Sanofi Recombinant Human Coagulation Factor IX Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 81. Sanofi Recombinant Human Coagulation Factor IX Product Portfolio Table 82. Sanofi Recent Developments Table 83. ChinaBiologic Company Information Table 84. ChinaBiologic Business Overview Table 85. ChinaBiologic Recombinant Human Coagulation Factor IX Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 86. ChinaBiologic Recombinant Human Coagulation Factor IX Product Portfolio Table 87. ChinaBiologic Recent Developments Table 88. Shuyang Company Information Table 89. Shuyang Business Overview Table 90. Shuyang Recombinant Human Coagulation Factor IX Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 91. Shuyang Recombinant Human Coagulation Factor IX Product Portfolio Table 92. Shuyang Recent Developments Table 93. Global Recombinant Human Coagulation Factor IX Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 94. Global Recombinant Human Coagulation Factor IX Sales by Region (2021-2026) & (k units) Table 95. Global Recombinant Human Coagulation Factor IX Sales Market Share by Region (2021-2026) Table 96. Global Recombinant Human Coagulation Factor IX Sales by Region (2027-2032) & (k units) Table 97. Global Recombinant Human Coagulation Factor IX Sales Market Share by Region (2027-2032) Table 98. Global Recombinant Human Coagulation Factor IX Revenue by Region (2021-2026) & (US$ Million) Table 99. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Region (2021-2026) Table 100. Global Recombinant Human Coagulation Factor IX Revenue by Region (2027-2032) & (US$ Million) Table 101. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Region (2027-2032) Table 102. North America Recombinant Human Coagulation Factor IX Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 103. North America Recombinant Human Coagulation Factor IX Sales by Country (2021-2026) & (k units) Table 104. North America Recombinant Human Coagulation Factor IX Sales by Country (2027-2032) & (k units) Table 105. North America Recombinant Human Coagulation Factor IX Revenue by Country (2021-2026) & (US$ Million) Table 106. North America Recombinant Human Coagulation Factor IX Revenue by Country (2027-2032) & (US$ Million) Table 107. Europe Recombinant Human Coagulation Factor IX Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. Europe Recombinant Human Coagulation Factor IX Sales by Country (2021-2026) & (k units) Table 109. Europe Recombinant Human Coagulation Factor IX Sales by Country (2027-2032) & (k units) Table 110. Europe Recombinant Human Coagulation Factor IX Revenue by Country (2021-2026) & (US$ Million) Table 111. Europe Recombinant Human Coagulation Factor IX Revenue by Country (2027-2032) & (US$ Million) Table 112. Asia Pacific Recombinant Human Coagulation Factor IX Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Asia Pacific Recombinant Human Coagulation Factor IX Sales by Country (2021-2026) & (k units) Table 114. Asia Pacific Recombinant Human Coagulation Factor IX Sales by Country (2027-2032) & (k units) Table 115. Asia Pacific Recombinant Human Coagulation Factor IX Revenue by Country (2021-2026) & (US$ Million) Table 116. Asia Pacific Recombinant Human Coagulation Factor IX Revenue by Country (2027-2032) & (US$ Million) Table 117. South America Recombinant Human Coagulation Factor IX Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. South America Recombinant Human Coagulation Factor IX Sales by Country (2021-2026) & (k units) Table 119. South America Recombinant Human Coagulation Factor IX Sales by Country (2027-2032) & (k units) Table 120. South America Recombinant Human Coagulation Factor IX Revenue by Country (2021-2026) & (US$ Million) Table 121. South America Recombinant Human Coagulation Factor IX Revenue by Country (2027-2032) & (US$ Million) Table 122. Middle East and Africa Recombinant Human Coagulation Factor IX Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. Middle East and Africa Recombinant Human Coagulation Factor IX Sales by Country (2021-2026) & (k units) Table 124. Middle East and Africa Recombinant Human Coagulation Factor IX Sales by Country (2027-2032) & (k units) Table 125. Middle East and Africa Recombinant Human Coagulation Factor IX Revenue by Country (2021-2026) & (US$ Million) Table 126. Middle East and Africa Recombinant Human Coagulation Factor IX Revenue by Country (2027-2032) & (US$ Million) Table 127. Global Recombinant Human Coagulation Factor IX Sales by Type (2021-2026) & (k units) Table 128. Global Recombinant Human Coagulation Factor IX Sales by Type (2027-2032) & (k units) Table 129. Global Recombinant Human Coagulation Factor IX Sales Market Share by Type (2021-2026) Table 130. Global Recombinant Human Coagulation Factor IX Sales Market Share by Type (2027-2032) Table 131. Global Recombinant Human Coagulation Factor IX Revenue by Type (2021-2026) & (US$ Million) Table 132. Global Recombinant Human Coagulation Factor IX Revenue by Type (2027-2032) & (US$ Million) Table 133. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Type (2021-2026) Table 134. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Type (2027-2032) Table 135. Global Recombinant Human Coagulation Factor IX Price by Type (2021-2026) & (USD/unit) Table 136. Global Recombinant Human Coagulation Factor IX Price by Type (2027-2032) & (USD/unit) Table 137. Global Recombinant Human Coagulation Factor IX Sales by Application (2021-2026) & (k units) Table 138. Global Recombinant Human Coagulation Factor IX Sales by Application (2027-2032) & (k units) Table 139. Global Recombinant Human Coagulation Factor IX Sales Market Share by Application (2021-2026) Table 140. Global Recombinant Human Coagulation Factor IX Sales Market Share by Application (2027-2032) Table 141. Global Recombinant Human Coagulation Factor IX Revenue by Application (2021-2026) & (US$ Million) Table 142. Global Recombinant Human Coagulation Factor IX Revenue by Application (2027-2032) & (US$ Million) Table 143. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Application (2021-2026) Table 144. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Application (2027-2032) Table 145. Global Recombinant Human Coagulation Factor IX Price by Application (2021-2026) & (USD/unit) Table 146. Global Recombinant Human Coagulation Factor IX Price by Application (2027-2032) & (USD/unit) Table 147. Key Raw Materials Table 148. Raw Materials Key Suppliers Table 149. Recombinant Human Coagulation Factor IX Distributors List Table 150. Recombinant Human Coagulation Factor IX Customers List Table 151. Recombinant Human Coagulation Factor IX Industry Trends Table 152. Recombinant Human Coagulation Factor IX Industry Drivers Table 153. Recombinant Human Coagulation Factor IX Industry Restraints Table 154. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Recombinant Human Coagulation Factor IX Product Image Figure 5. Global Recombinant Human Coagulation Factor IX Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Recombinant Human Coagulation Factor IX Market Size (2021-2032) & (US$ Million) Figure 7. Global Recombinant Human Coagulation Factor IX Sales (2021-2032) & (k units) Figure 8. Global Recombinant Human Coagulation Factor IX Average Price (USD/unit) & (2021-2032) Figure 9. 500 IU/Bottle Product Image Figure 10. 250 IU/Bottle Product Image Figure 11. 2000 IU/Bottle Product Image Figure 12. 1000 IU/Bottle Product Image Figure 13. Adult Patients Product Image Figure 14. Child Patients Product Image Figure 15. Global Recombinant Human Coagulation Factor IX Revenue Share by Manufacturers in 2025 Figure 16. Global Manufacturers of Recombinant Human Coagulation Factor IX, Manufacturing Sites & Headquarters Figure 17. Global Top 5 and 10 Recombinant Human Coagulation Factor IX Players Market Share by Revenue in 2025 Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Recombinant Human Coagulation Factor IX Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 20. Global Recombinant Human Coagulation Factor IX Sales by Region in 2025 Figure 21. Global Recombinant Human Coagulation Factor IX Revenue by Region in 2025 Figure 22. North America Recombinant Human Coagulation Factor IX Market Size by Country in 2025 Figure 23. North America Recombinant Human Coagulation Factor IX Sales Market Share by Country (2021-2032) Figure 24. North America Recombinant Human Coagulation Factor IX Revenue Market Share by Country (2021-2032) Figure 25. United States Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Canada Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Mexico Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe Recombinant Human Coagulation Factor IX Market Size by Country in 2025 Figure 29. Europe Recombinant Human Coagulation Factor IX Sales Market Share by Country (2021-2032) Figure 30. Europe Recombinant Human Coagulation Factor IX Revenue Market Share by Country (2021-2032) Figure 31. Germany Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Russia Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Spain Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Netherlands Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Switzerland Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Sweden Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Poland Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Asia Pacific Recombinant Human Coagulation Factor IX Market Size by Country in 2025 Figure 42. Asia Pacific Recombinant Human Coagulation Factor IX Sales Market Share by Country (2021-2032) Figure 43. Asia Pacific Recombinant Human Coagulation Factor IX Revenue Market Share by Country (2021-2032) Figure 44. China Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Japan Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South Korea Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. India Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Australia Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Taiwan Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. South America Recombinant Human Coagulation Factor IX Market Size by Country in 2025 Figure 53. South America Recombinant Human Coagulation Factor IX Sales Market Share by Country (2021-2032) Figure 54. South America Recombinant Human Coagulation Factor IX Revenue Market Share by Country (2021-2032) Figure 55. Brazil Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Argentina Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Chile Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Middle East and Africa Recombinant Human Coagulation Factor IX Market Size by Country in 2025 Figure 59. Middle East and Africa Recombinant Human Coagulation Factor IX Sales Market Share by Country (2021-2032) Figure 60. Middle East and Africa Recombinant Human Coagulation Factor IX Revenue Market Share by Country (2021-2032) Figure 61. Egypt Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. South Africa Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Israel Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Türkiye Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. GCC Countries Recombinant Human Coagulation Factor IX Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Global Recombinant Human Coagulation Factor IX Sales Market Share by Type (2021-2032) Figure 67. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Type (2021-2032) Figure 68. Global Recombinant Human Coagulation Factor IX Price (USD/unit) by Type (2021-2032) Figure 69. Global Recombinant Human Coagulation Factor IX Sales Market Share by Application (2021-2032) Figure 70. Global Recombinant Human Coagulation Factor IX Revenue Market Share by Application (2021-2032) Figure 71. Global Recombinant Human Coagulation Factor IX Price (USD/unit) by Application (2021-2032) Figure 72. Recombinant Human Coagulation Factor IX Value Chain Figure 73. Recombinant Human Coagulation Factor IX Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Recombinant Human Coagulation Factor IX Industry Opportunities and Challenges

Scope & coverage.

Types
  • 500 IU/Bottle
  • 250 IU/Bottle
  • 2000 IU/Bottle
  • 1000 IU/Bottle
Applications
  • Adult Patients
  • Child Patients
Companies covered
  • Bio-Techne
  • Cayman
  • Cusabio
  • Grifols
  • IDELVION
  • NovoPro Bioscience
  • Octapharma
  • Sino Biological
  • Baxter
  • Biogen
  • Diagbio
  • Hualan Bio
  • Sanofi
  • ChinaBiologic
  • Shuyang

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Recombinant Human Coagulation Factor IX Market Size (2021-2032)
  4. 2.2.2 Global Recombinant Human Coagulation Factor IX Sales (2021-2032)
  5. 2.2.3 Global Recombinant Human Coagulation Factor IX Market Average Price (2021-2032)
  6. 2.3 Recombinant Human Coagulation Factor IX by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 500 IU/Bottle
  9. 2.3.3 250 IU/Bottle
  10. 2.3.4 2000 IU/Bottle
  11. 2.3.5 1000 IU/Bottle
  12. 2.4 Recombinant Human Coagulation Factor IX by Application
  13. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  14. 2.4.2 Adult Patients
  15. 2.4.3 Child Patients
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Recombinant Human Coagulation Factor IX Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Recombinant Human Coagulation Factor IX Sales (k units) of Manufacturers (2021-2026)
  3. 3.3 Global Recombinant Human Coagulation Factor IX Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Recombinant Human Coagulation Factor IX Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Recombinant Human Coagulation Factor IX Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Recombinant Human Coagulation Factor IX, Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Recombinant Human Coagulation Factor IX, Product Type & Application
  8. 3.8 Global Manufacturers of Recombinant Human Coagulation Factor IX, Established Date
  9. 3.9 Global Recombinant Human Coagulation Factor IX Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Bio-Techne
  2. 4.1.1 Bio-Techne Company Information
  3. 4.1.2 Bio-Techne Business Overview
  4. 4.1.3 Bio-Techne Recombinant Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Bio-Techne Recombinant Human Coagulation Factor IX Product Portfolio
  6. 4.1.5 Bio-Techne Recent Developments
  7. 4.2 Cayman
  8. 4.2.1 Cayman Company Information
  9. 4.2.2 Cayman Business Overview
  10. 4.2.3 Cayman Recombinant Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Cayman Recombinant Human Coagulation Factor IX Product Portfolio
  12. 4.2.5 Cayman Recent Developments
  13. 4.3 Cusabio
  14. 4.3.1 Cusabio Company Information
  15. 4.3.2 Cusabio Business Overview
  16. 4.3.3 Cusabio Recombinant Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Cusabio Recombinant Human Coagulation Factor IX Product Portfolio
  18. 4.3.5 Cusabio Recent Developments
  19. 4.4 Grifols
  20. 4.4.1 Grifols Company Information
  21. 4.4.2 Grifols Business Overview
  22. 4.4.3 Grifols Recombinant Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Grifols Recombinant Human Coagulation Factor IX Product Portfolio
  24. 4.4.5 Grifols Recent Developments
  25. 4.5 IDELVION
  26. 4.5.1 IDELVION Company Information
  27. 4.5.2 IDELVION Business Overview
  28. 4.5.3 IDELVION Recombinant Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 IDELVION Recombinant Human Coagulation Factor IX Product Portfolio
  30. 4.5.5 IDELVION Recent Developments
  31. 4.6 NovoPro Bioscience
  32. 4.6.1 NovoPro Bioscience Company Information
  33. 4.6.2 NovoPro Bioscience Business Overview
  34. 4.6.3 NovoPro Bioscience Recombinant Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 NovoPro Bioscience Recombinant Human Coagulation Factor IX Product Portfolio
  36. 4.6.5 NovoPro Bioscience Recent Developments
  37. 4.7 Octapharma
  38. 4.7.1 Octapharma Company Information
  39. 4.7.2 Octapharma Business Overview
  40. 4.7.3 Octapharma Recombinant Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Octapharma Recombinant Human Coagulation Factor IX Product Portfolio
  42. 4.7.5 Octapharma Recent Developments
  43. 4.8 Sino Biological
  44. 4.8.1 Sino Biological Company Information
  45. 4.8.2 Sino Biological Business Overview
  46. 4.8.3 Sino Biological Recombinant Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Sino Biological Recombinant Human Coagulation Factor IX Product Portfolio
  48. 4.8.5 Sino Biological Recent Developments
  49. 4.9 Baxter
  50. 4.9.1 Baxter Company Information
  51. 4.9.2 Baxter Business Overview
  52. 4.9.3 Baxter Recombinant Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Baxter Recombinant Human Coagulation Factor IX Product Portfolio
  54. 4.9.5 Baxter Recent Developments
  55. 4.10 Biogen
  56. 4.10.1 Biogen Company Information
  57. 4.10.2 Biogen Business Overview
  58. 4.10.3 Biogen Recombinant Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Biogen Recombinant Human Coagulation Factor IX Product Portfolio
  60. 4.10.5 Biogen Recent Developments
  61. 4.11 Diagbio
  62. 4.11.1 Diagbio Company Information
  63. 4.11.2 Diagbio Business Overview
  64. 4.11.3 Diagbio Recombinant Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Diagbio Recombinant Human Coagulation Factor IX Product Portfolio
  66. 4.11.5 Diagbio Recent Developments
  67. 4.12 Hualan Bio
  68. 4.12.1 Hualan Bio Company Information
  69. 4.12.2 Hualan Bio Business Overview
  70. 4.12.3 Hualan Bio Recombinant Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Hualan Bio Recombinant Human Coagulation Factor IX Product Portfolio
  72. 4.12.5 Hualan Bio Recent Developments
  73. 4.13 Sanofi
  74. 4.13.1 Sanofi Company Information
  75. 4.13.2 Sanofi Business Overview
  76. 4.13.3 Sanofi Recombinant Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Sanofi Recombinant Human Coagulation Factor IX Product Portfolio
  78. 4.13.5 Sanofi Recent Developments
  79. 4.14 ChinaBiologic
  80. 4.14.1 ChinaBiologic Company Information
  81. 4.14.2 ChinaBiologic Business Overview
  82. 4.14.3 ChinaBiologic Recombinant Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 ChinaBiologic Recombinant Human Coagulation Factor IX Product Portfolio
  84. 4.14.5 ChinaBiologic Recent Developments
  85. 4.15 Shuyang
  86. 4.15.1 Shuyang Company Information
  87. 4.15.2 Shuyang Business Overview
  88. 4.15.3 Shuyang Recombinant Human Coagulation Factor IX Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 Shuyang Recombinant Human Coagulation Factor IX Product Portfolio
  90. 4.15.5 Shuyang Recent Developments
5 Global Recombinant Human Coagulation Factor IX Market Scenario by Region
  1. 5.1 Global Recombinant Human Coagulation Factor IX Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Recombinant Human Coagulation Factor IX Sales by Region: 2021-2032
  3. 5.2.1 Global Recombinant Human Coagulation Factor IX Sales by Region: 2021-2026
  4. 5.2.2 Global Recombinant Human Coagulation Factor IX Sales by Region: 2027-2032
  5. 5.3 Global Recombinant Human Coagulation Factor IX Revenue by Region: 2021-2032
  6. 5.3.1 Global Recombinant Human Coagulation Factor IX Revenue by Region: 2021-2026
  7. 5.3.2 Global Recombinant Human Coagulation Factor IX Revenue by Region: 2027-2032
  8. 5.4 North America Recombinant Human Coagulation Factor IX Market Facts & Figures by Country
  9. 5.4.1 North America Recombinant Human Coagulation Factor IX Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Recombinant Human Coagulation Factor IX Sales by Country (2021-2032)
  11. 5.4.3 North America Recombinant Human Coagulation Factor IX Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Recombinant Human Coagulation Factor IX Market Facts & Figures by Country
  16. 5.5.1 Europe Recombinant Human Coagulation Factor IX Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Recombinant Human Coagulation Factor IX Sales by Country (2021-2032)
  18. 5.5.3 Europe Recombinant Human Coagulation Factor IX Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Recombinant Human Coagulation Factor IX Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Recombinant Human Coagulation Factor IX Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Recombinant Human Coagulation Factor IX Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Recombinant Human Coagulation Factor IX Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Recombinant Human Coagulation Factor IX Market Facts & Figures by Country
  41. 5.7.1 South America Recombinant Human Coagulation Factor IX Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Recombinant Human Coagulation Factor IX Sales by Country (2021-2032)
  43. 5.7.3 South America Recombinant Human Coagulation Factor IX Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Recombinant Human Coagulation Factor IX Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Recombinant Human Coagulation Factor IX Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Recombinant Human Coagulation Factor IX Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Recombinant Human Coagulation Factor IX Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Recombinant Human Coagulation Factor IX Sales by Type (2021-2032)
  2. 6.1.1 Global Recombinant Human Coagulation Factor IX Sales by Type (2021-2032) & (k units)
  3. 6.1.2 Global Recombinant Human Coagulation Factor IX Sales Market Share by Type (2021-2032)
  4. 6.2 Global Recombinant Human Coagulation Factor IX Revenue by Type (2021-2032)
  5. 6.2.1 Global Recombinant Human Coagulation Factor IX Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Recombinant Human Coagulation Factor IX Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Recombinant Human Coagulation Factor IX Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Recombinant Human Coagulation Factor IX Sales by Application (2021-2032)
  2. 7.1.1 Global Recombinant Human Coagulation Factor IX Sales by Application (2021-2032) & (k units)
  3. 7.1.2 Global Recombinant Human Coagulation Factor IX Sales Market Share by Application (2021-2032)
  4. 7.2 Global Recombinant Human Coagulation Factor IX Revenue by Application (2021-2032)
  5. 7.2.1 Global Recombinant Human Coagulation Factor IX Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Recombinant Human Coagulation Factor IX Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Recombinant Human Coagulation Factor IX Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Recombinant Human Coagulation Factor IX Value Chain Analysis
  2. 8.1.1 Recombinant Human Coagulation Factor IX Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Recombinant Human Coagulation Factor IX Production Mode & Process
  5. 8.2 Recombinant Human Coagulation Factor IX Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Recombinant Human Coagulation Factor IX Distributors
  8. 8.2.3 Recombinant Human Coagulation Factor IX Customers
9 Global Recombinant Human Coagulation Factor IX Analyzing Market Dynamics
  1. 9.1 Recombinant Human Coagulation Factor IX Industry Trends
  2. 9.2 Recombinant Human Coagulation Factor IX Industry Drivers
  3. 9.3 Recombinant Human Coagulation Factor IX Industry Opportunities and Challenges
  4. 9.4 Recombinant Human Coagulation Factor IX Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research, Inc.
      Talk to an analyst